Biogen Exercises its Option to Acquire TMS-007 for Acute Ischemic Stroke

 Biogen Exercises its Option to Acquire TMS-007 for Acute Ischemic Stroke

Shots:

  • Biogen’s decision of acquisition of TMS-007 based on the safety, imaging, and clinical outcome data from the P-IIa study which showed positive impacts on both blood vessel reopening in the brain, as well as patient functional recovery with no incidence of sICH
  • TMS to receive $18M upon acquisition of TMS-007 and is eligible to receive up to $335M as post-acquisition payment upon the achievement of certain milestones along with royalties on annual WW net sales
  • Biogen will be responsible for the development, manufacturing, and commercialization of TMS-007, following the acquisition and is currently assessing the next steps for the clinical development of TMS-007

Click here to­ read full press release/ article | Ref: GLOBE NEWSWIRE | Image: Biogen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post